TOMMY-HILFIGER
6.1.2021 08:32:19 CET | Business Wire | Press release
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], is pleased to announce that applications for the third edition of the Tommy Hilfiger Fashion Frontier Challenge open from January 6 until March 8, 2021. The global program aims to support entrepreneurial start-up and scale-up stage businesses that develop solutions that make a positive social impact on the fashion landscape. Since its inception in 2018, the Tommy Hilfiger Fashion Frontier Challenge has awarded €350,000 to entrepreneurs who stand up for what they believe in and are committed to driving change within their communities. Building on Tommy Hilfiger’s sustainability vision to Waste Nothing and Welcome All , the third edition of the program strives to amplify and support black, indigenous and people of color (BIPOC) entrepreneurs who are working to advance their communities and foster a more inclusive future of fashion. Consumers are also invited to get involved and help judge submissions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105006033/en/
“The Tommy Hilfiger Fashion Frontier Challenge puts a spotlight on entrepreneurs putting their heart and soul into making a positive social impact in our industry,” said Tommy Hilfiger. “This year, we want to showcase an even more diverse range of perspectives, ideas and communities by supporting BIPOC entrepreneurs. We have a responsibility to drive change across the fashion landscape, and I am honored to further our commitment to inclusivity and equal representation through the upcoming Tommy Hilfiger Fashion Frontier Challenge.”
Interested businesses are invited to submit project proposals that focus on creating a more inclusive fashion value-chain. Applicants will be narrowed down to six finalists who will be invited to develop their project plans virtually with the support of dedicated Tommy Hilfiger and external subject-matter experts. With training from an experienced pitch coach, finalists will present their final concept to a prestigious jury panel and associate audience at the global Tommy Hilfiger Fashion Frontier Challenge final event to be held in early 2022.
In a bid to further its ambitions of inclusivity, Tommy Hilfiger has extended an invitation to consumers to join in as Consumer Judges and help decide this year’s finalists. Consumer Judges will be tasked with narrowing down finalists from 200 to 50, with each being sent at least four applications to judge via the brand’s online microsite. Applications to become a Consumer Judge can be made through https://responsibility.pvh.com/tommy/fashion-frontier-challenge/ and close February 8th.
The following program prizes have been increased from previous years, providing winners with the finance and knowledge to grow their business idea:
- A total of €200,000 awarded between winners and a chance at an additional €15,000 prize for winning the “Audience Favorite Vote”
- A year-long mentorship with global Tommy Hilfiger’s internal experts,
- A place on the INSEAD Social Entrepreneurship Program (ISEP)
- A year-long INSEAD mentorship
“While the fashion industry has taken positive steps towards becoming more inclusive and diverse, there is still more to be done,” said Martijn Hagman, CEO, Tommy Hilfiger Global. “Through the Tommy Hilfiger Fashion Frontier Challenge, we are furthering our commitment towards representation and diversity and helping drive the changes we most want, and need, to see.”
Tommy Hilfiger’s mission is to become a fashion company that Wastes Nothing and Welcomes All ; a leading sustainable designer lifestyle company through how it creates its product, manages its operations, and connects with its communities and stakeholders. More information about Tommy Hilfiger’s sustainability journey, which is powered by PVH’s Forward Fashion strategy, can be found on https://global.tommy.com/en_int/about-us-corporate-sustainability .
More information about the Tommy Hilfiger Fashion Frontier Challenge , including how to apply, is available here: https://responsibility.pvh.com/tommy/fashion-frontier-challenge/ .
Friends and followers of the brand are invited to join the conversation on social media using #TommyHilfiger, and @TommyHilfiger.
# # #
About Tommy Hilfiger
With a brand portfolio that includes TOMMY HILFIGER and TOMMY JEANS , Tommy Hilfiger is one of the world’s most recognized premium designer lifestyle groups. Its focus is designing and marketing high-quality men’s tailored clothing and sportswear, women’s collection apparel and sportswear, kidswear, denim collections, underwear (including robes, sleepwear and loungewear), footwear and accessories. Through select licensees, Tommy Hilfiger offers complementary lifestyle products such as eyewear, watches, fragrance, swimwear, socks, small leather goods, home goods and luggage. The TOMMY JEANS product line consists of jeanswear and footwear for men and women, accessories, and fragrance. Merchandise under the TOMMY HILFIGER and TOMMY JEANS brands is available to consumers worldwide through an extensive network of TOMMY HILFIGER and TOMMY JEANS retail stores, leading specialty and department stores, select online retailers, and at tommy .com.
About PVH Corp.
PVH is one of the most admired fashion and lifestyle companies in the world. We power brands that drive fashion forward – for good. Our brand portfolio includes the iconic Calvin Klein , TOMMY HILFIGER , Van Heusen , IZOD , ARROW, Warner’s , Olga and Geoffrey Beene brands, as well as the digital-centric True&Co. intimates brand. We market a variety of goods under these and other nationally and internationally known owned and licensed brands. PVH has over 40,000 associates operating in over 40 countries and $9.9 billion in annual revenues. That's the Power of Us. That’s the Power of PVH.
Follow us on Facebook , Instagram , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105006033/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
